Sector News

AstraZeneca oncology head jumps ship to become Innate CEO

December 20, 2016
Life sciences

AstraZeneca is losing its head of oncology, Mondher Mahjoubi, who is departing to lead French biotech company Innate Pharma.

Innate said on Monday that Mahjoubi would take over as chief executive on Dec. 30, replacing Herve Brailly who is moving on to become chairman of the supervisory board.

The loss of Mahjoubi is a setback for AstraZeneca, given the British drugmaker’s focus on new cancer treatments. Mahjoubi previously worked at Roche’s (ROG.S) Genentech unit before joining AstraZeneca, where he has helped lead oncology strategy.

His departure comes ahead of key clinical trial read-outs for the company’s experimental immunotherapy drugs.

AstraZeneca said Mahjoubi’s successor would be announced shortly.

For Mahjoubi, the move to Innate offers the opportunity to run a company that specialises in immuno-oncology, which is now transforming the fight against several different types of cancer.

Innate said he would be paid a base salary of 470,000 euros ($490,000). He will also get free shares in the company and be eligible for pay and share bonuses, if certain targets were met.

Shares in Innate were 4 percent higher by 1230 GMT while AstraZeneca slipped 1.4 percent.

By Ben Hirschler

Source: Reuters

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach